Evidence map›Paper›PMID 41332315›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Synthetic Lethal Therapy Based on Dimorphism for Systemic Infection of Drug-Resistant Candida albicans.

Yang Gao, Jiahe Su, Jiawei Yuan, Qinyan Cao, Yue Wu, Yuyang Xiao, Guang Yang, Ruomu Xia, Jingpeng Yang, Yanan Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yang GaoState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Jiahe SuState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Jiawei YuanState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Qinyan CaoState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Yue WuState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Yuyang XiaoState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Guang YangState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Ruomu XiaCollege of Life Sciences, Beijing Normal University, Beijing, 100091, China.
Jingpeng YangState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Yanan LiState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Lina WuState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
He HuangState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.
Lingtong MengState Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China.ORCID https://orcid.org/0000-0002-9601-5260

Funding

The Jiangsu Basic Research Center for Synthetic Biology BK20233003The Natural Science Foundation of the Jiangsu Higher Education Institutions 24KJB350003
6 · The paper itself

Abstract

Systemic infections of Candida albicans are dire, with a mortality rate reaching 60%. The transformation between the yeast and hyphae states of C. albicans resists existing medications and the body's immune defenses. Some currently available drugs only inhibit the growth of the yeast-form of C. albicans. Therefore, a synthetic lethal therapy that leverages the dimorphism of C. albicans is developed. This therapy utilizes rapamycin to eliminate yeast-like C. albicans through the mammalian target of rapamycin pathway. Simultaneously, deferasirox restricts iron resources, thereby inhibiting polarization and hyphae formation. As a result, C. albicans cannot evade the lethal effects of drugs and immune cells by undergoing morphological transformations. Furthermore, inspired by the recognition process of fungi by macrophages, macrophage membranes with high expression of dectin-1 are utilized to deliver rapamycin and deferasirox. The synthetic lethal therapy based on dimorphism significantly improves the survival rate of mice with systemic infections, thereby offering a promising strategy for treating drug-resistant C. albicans infections.

Indexed as

Antifungal AgentsCandida albicansCandidiasisDrug Resistance, FungalSirolimusAnimalsDeferasiroxDisease Models, AnimalFemaleHumansHyphaeMiceAntifungal AgentsDeferasiroxSirolimusCandida albicansdimorphismhyphaerapamycinsynthetic lethal therapies

Identifiers

PMID41332315
PMCPMC12931174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.